Lantheus Holdings, Inc. LNTH
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances
Chart by TradingView
4/9
Piotroski F — financial health
4.61
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.5B | $233.6M | $942.0M | — | $1.1B |
| 2024 | $1.5B | $312.4M | $988.3M | — | $1.1B |
| 2023 | $1.3B | $326.7M | $709.5M | — | $815.9M |
| 2022 | $935.1M | $28.1M | $581.7M | — | $447.1M |
| 2021 | $425.2M | -$71.3M | $187.7M | — | $464.4M |
| 2020 | $339.4M | -$13.5M | $138.8M | — | $514.2M |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 4.61 (safe)
- Working capital / assets 0.254
- Retained earnings / assets 0.305
- EBIT / assets 0.14
- Equity / liabilities 0.958
Source: SEC EDGAR filings · CIK 0001521036 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.